PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis
NYSE:PBH - New York Stock Exchange, Inc. - US74112D1019 - Common Stock - Currency: USD
PBH gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. PBH scores excellent points on both the profitability and health parts. This is a solid base for a good stock. PBH has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year PBH was profitable.
PBH had a positive operating cash flow in the past year.
Of the past 5 years PBH 4 years were profitable.
PBH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
PBH has a Return On Assets of 6.31%. This is amongst the best in the industry. PBH outperforms 90.67% of its industry peers.
PBH's Return On Equity of 11.70% is amongst the best of the industry. PBH outperforms 88.08% of its industry peers.
PBH's Return On Invested Capital of 8.02% is amongst the best of the industry. PBH outperforms 85.49% of its industry peers.
PBH had an Average Return On Invested Capital over the past 3 years of 8.16%. This is significantly below the industry average of 14.87%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.31% | ||
| ROE | 11.7% | ||
| ROIC | 8.02% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
1.3 Margins
PBH has a Profit Margin of 18.86%. This is amongst the best in the industry. PBH outperforms 92.23% of its industry peers.
In the last couple of years the Profit Margin of PBH has grown nicely.
With an excellent Operating Margin value of 30.70%, PBH belongs to the best of the industry, outperforming 94.82% of the companies in the same industry.
PBH's Operating Margin has been stable in the last couple of years.
PBH has a better Gross Margin (55.76%) than 65.80% of its industry peers.
PBH's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.7% | ||
| PM (TTM) | 18.86% | ||
| GM | 55.76% |
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PBH is destroying value.
PBH has less shares outstanding than it did 1 year ago.
PBH has less shares outstanding than it did 5 years ago.
PBH has a better debt/assets ratio than last year.
2.2 Solvency
PBH has an Altman-Z score of 2.87. This is not the best score and indicates that PBH is in the grey zone with still only limited risk for bankruptcy at the moment.
PBH's Altman-Z score of 2.87 is fine compared to the rest of the industry. PBH outperforms 70.98% of its industry peers.
PBH has a debt to FCF ratio of 4.17. This is a neutral value as PBH would need 4.17 years to pay back of all of its debts.
PBH's Debt to FCF ratio of 4.17 is amongst the best of the industry. PBH outperforms 86.01% of its industry peers.
A Debt/Equity ratio of 0.55 indicates that PBH is somewhat dependend on debt financing.
PBH has a worse Debt to Equity ratio (0.55) than 62.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 4.17 | ||
| Altman-Z | 2.87 |
ROIC/WACC0.86
WACC9.37%
2.3 Liquidity
PBH has a Current Ratio of 4.20. This indicates that PBH is financially healthy and has no problem in meeting its short term obligations.
PBH has a Current ratio of 4.20. This is in the better half of the industry: PBH outperforms 63.21% of its industry peers.
A Quick Ratio of 2.82 indicates that PBH has no problem at all paying its short term obligations.
The Quick ratio of PBH (2.82) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.2 | ||
| Quick Ratio | 2.82 |
3. Growth
3.1 Past
PBH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.63%, which is quite good.
Measured over the past years, PBH shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.88% on average per year.
Looking at the last year, PBH shows a small growth in Revenue. The Revenue has grown by 1.10% in the last year.
Measured over the past years, PBH shows a small growth in Revenue. The Revenue has been growing by 3.39% on average per year.
EPS 1Y (TTM)8.63%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%34.69%
Revenue 1Y (TTM)1.1%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%7.05%
3.2 Future
Based on estimates for the next years, PBH will show a small growth in Earnings Per Share. The EPS will grow by 4.65% on average per year.
PBH is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.00% yearly.
EPS Next Y6.35%
EPS Next 2Y5.88%
EPS Next 3Y5.22%
EPS Next 5Y4.65%
Revenue Next Year1.66%
Revenue Next 2Y1.87%
Revenue Next 3Y1.95%
Revenue Next 5Y2%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 16.75 indicates a correct valuation of PBH.
Based on the Price/Earnings ratio, PBH is valued cheaply inside the industry as 84.46% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 27.51, PBH is valued a bit cheaper.
With a Price/Forward Earnings ratio of 15.75, PBH is valued correctly.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PBH indicates a somewhat cheap valuation: PBH is cheaper than 77.72% of the companies listed in the same industry.
PBH's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 35.58.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.75 | ||
| Fwd PE | 15.75 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PBH indicates a rather cheap valuation: PBH is cheaper than 84.46% of the companies listed in the same industry.
86.53% of the companies in the same industry are more expensive than PBH, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.36 | ||
| EV/EBITDA | 12.33 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PBH has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.64
PEG (5Y)1.89
EPS Next 2Y5.88%
EPS Next 3Y5.22%
5. Dividend
5.1 Amount
No dividends for PBH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:PBH (7/15/2025, 10:49:40 AM)
75.89
-0.53 (-0.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners106.21%
Inst Owner Change0%
Ins Owners1.41%
Ins Owner Change4.43%
Market Cap3.74B
Analysts78
Price Target92.62 (22.05%)
Short Float %3.42%
Short Ratio4.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.47%
Min EPS beat(2)0.64%
Max EPS beat(2)4.3%
EPS beat(4)3
Avg EPS beat(4)2.01%
Min EPS beat(4)-0.47%
Max EPS beat(4)4.3%
EPS beat(8)5
Avg EPS beat(8)-0.35%
EPS beat(12)8
Avg EPS beat(12)-46.35%
EPS beat(16)12
Avg EPS beat(16)-31.94%
Revenue beat(2)2
Avg Revenue beat(2)0.9%
Min Revenue beat(2)0.33%
Max Revenue beat(2)1.46%
Revenue beat(4)3
Avg Revenue beat(4)0.74%
Min Revenue beat(4)-0.39%
Max Revenue beat(4)1.57%
Revenue beat(8)3
Avg Revenue beat(8)-0.39%
Revenue beat(12)6
Avg Revenue beat(12)0.09%
Revenue beat(16)10
Avg Revenue beat(16)1.7%
PT rev (1m)0%
PT rev (3m)-0.77%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.02%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.36%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.75 | ||
| Fwd PE | 15.75 | ||
| P/S | 3.28 | ||
| P/FCF | 15.36 | ||
| P/OCF | 14.85 | ||
| P/B | 2.04 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.33 |
EPS(TTM)4.53
EY5.97%
EPS(NY)4.82
Fwd EY6.35%
FCF(TTM)4.94
FCFY6.51%
OCF(TTM)5.11
OCFY6.73%
SpS23.11
BVpS37.27
TBVpS-20.07
PEG (NY)2.64
PEG (5Y)1.89
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.31% | ||
| ROE | 11.7% | ||
| ROCE | 10.6% | ||
| ROIC | 8.02% | ||
| ROICexc | 8.27% | ||
| ROICexgc | 70.49% | ||
| OM | 30.7% | ||
| PM (TTM) | 18.86% | ||
| GM | 55.76% | ||
| FCFM | 21.38% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexcg growth 3Y-14.1%
ROICexcg growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score7
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 4.17 | ||
| Debt/EBITDA | 2.67 | ||
| Cap/Depr | 27.26% | ||
| Cap/Sales | 0.72% | ||
| Interest Coverage | 7.31 | ||
| Cash Conversion | 66.29% | ||
| Profit Quality | 113.37% | ||
| Current Ratio | 4.2 | ||
| Quick Ratio | 2.82 | ||
| Altman-Z | 2.87 |
F-Score7
WACC9.37%
ROIC/WACC0.86
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.63%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%34.69%
EPS Next Y6.35%
EPS Next 2Y5.88%
EPS Next 3Y5.22%
EPS Next 5Y4.65%
Revenue 1Y (TTM)1.1%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%7.05%
Revenue Next Year1.66%
Revenue Next 2Y1.87%
Revenue Next 3Y1.95%
Revenue Next 5Y2%
EBIT growth 1Y1.99%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year11.34%
EBIT Next 3Y4.95%
EBIT Next 5Y3.8%
FCF growth 1Y1.64%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y1.04%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%